StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) company profile

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$144.35−0.25 (-0.17%)

Close on Nov 17, 2026Market cap $2.08BP/E –Yield –

About Palvella Therapeutics

Pharmaceutical Preparations, SIC 2834

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapies for individuals suffering from serious, rare skin diseases and vascular malformations that lack approved treatments. The company utilizes its proprietary QTORIN drug development platform to produce topical therapies designed to penetrate deep skin layers. Its lead product candidate is QTORIN rapamycin, an anhydrous gel in clinical development for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Additionally, the company develops QTORIN pitavastatin to treat disseminated superficial actinic porokeratosis. Its target patient populations include individuals diagnosed with these rare dermatologic and vascular conditions.

The company is based in Wayne, Pennsylvania, where it maintains its principal executive offices. Its clinical development activities include studies conducted across specialized vascular anomaly centers located in the United States. Following a merger, it operates with Legacy Palvella as a wholly owned subsidiary.

Summary of the business section of Palvella Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Palvella Therapeutics, Inc.
Headquarters
Wayne, PA
Address
353 W. Lancaster Avenue, Suite 200 19087
Phone
(484) 253-1461
Employees
29, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
PVLA
Former tickers
PIRS until Jan 13, 2025
Exchange
Nasdaq
IPO date
Jan 2, 2015
Shares outstanding
14M, Jul 31, 2026
Public float
$196.70M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-80 reverse, Apr 23, 2024; 9-for-4, Dec 5, 2014
SEC CIK
1583648
CUSIP
697947109
ISIN
US6979471090
FIGI
BBG0055C3N57
Share class FIGI
BBG0055C3N66
LEI
254900AJDH8PAOOI5T33
EIN
30-0784346

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Wes KaupinenPresident and CEO, Director1,607,228
Jeffrey S. MartiniChief Scientific Officer0
Kathleen GoinChief Operating Officer0
Matthew E. KorenbergCFO, Treasurer1,000
Ashley Hartmann KlineChief Commercial Officer–
Palvella Therapeutics, Inc.CFO and Treasurer–
George M. JenkinsDirector146,132
Christopher P. KiritsyDirector250
Matthew PaulsDirector–
John DouxDirector–
Tadd S. WesselDirector–
Elaine J. HeronDirector53,691
Todd C. DavisDirector112,547
James A. GeraghtyDirector0

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.40M$57.10M$1.98M$126–
FY2024
Stephen Yoder
$1.43M$1.38M$1.20M$14–
FY2024
Wesley HKaupinen
$5.15M$4.55M$1.20M$14–
FY2023$1.36M$553.95K$717.24K$18–
FY2022$2.06M-$526.88K$954.08K$28–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Wesley H. Kaupinen
President and Chief Executive Officer
$575.00K$2.47M$359.38K$643$3.40M-37%
Kathleen Goin
Chief Operating Officer
$481.30K$1.31M$192.52K–$1.98M+76%
Matthew E. Korenberg
Chief Financial Officer
$475.30K$1.31M$190.12K–$1.97M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of March 25, 2026, we had 29 full-time employees, of which two have Ph.Ds.”

Corporate history

Events identified from SEC filings

DateEventDetails
Dec 16, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 12, 2024Name changeName changed from PIERIS PHARMACEUTICALS, INC. to Palvella Therapeutics, Inc.
Aug 9, 2024MergerRegistration of securities for a merger or exchange offer (S-4)
May 19, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 7, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 24, 2015ListingRegistration of securities on an exchange (Form 8-A)
Jan 15, 2015Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 18, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 18, 2014Name changeName changed from Marika Inc. to PIERIS PHARMACEUTICALS, INC.
Dec 18, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)

See a number that looks wrong?